Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archderm.144.1.123 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
Drug Saf
October 2009
Department of Pharmacy, Beaujon University Hospital-Paris 7, Hôpital Beaujon, Clichy, France.
Sunitinib is a novel, oral, multi-targeted tyrosine kinase inhibitor with antiproliferative effects against cancer cells and antiangiogenic properties. Sunitinib was recently approved for the first-line treatment of patients with advanced renal cell carcinoma (RCC) and for the treatment of patients with gastrointestinal stromal tumours (GIST) after disease progression or intolerance to imatinib therapy. The main purpose of this benefit-risk assessment is to review data on sunitinib efficacy along with its toxicity in patients with GIST and RCC.
View Article and Find Full Text PDFSafety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
J Clin Oncol
January 2006
Department of Medicine, Gustave-Roussy Institute, Villejuif, France.
Purpose: To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies.
Patients And Methods: Sunitinib was given orally for 4 weeks every 6 weeks.
Results: Twenty-eight patients received doses ranging from 15 to 59 mg/m2 (ranging from 50 mg every other day to 150 mg/d).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!